...601 Course - TERM PAPER Financial Statement Analysis & Valuation AMBEE PharmaceuticalsLtd. ENTERPRISE VALUATION & ANALYSIS OF BUSINESS AMBEE Pharmaceuticals Limited T able of Contents Chapter - 01 Chapter - 02 Chapter - 03 Chapter - 04 Chapter - 05 About the Company Strategy Analysis Valuation Conclusion Annexure ………………………… ………………………… ………………………… ………………………… 01 03 11 21 A M B E E P H A R M A : V A L U A T I O N 1 Chapter About the Company The company’s operation & historical performances were moderate and they were not leading the market from their inception A MBEE PHARMACEUTICALS LTD., was established in 1976 in Bangladesh. This public limited company was registered under the companies Act, 1913 and was incorporated in Bangladesh on 4th February 1976. Ambee has a joint venture with a famous multinational company Medimpex of Hungary. Ambee started its operation with modest 17 joint ventured products and is now running in full swing with 76 products. They have Tablets, Capsules, Liquids, and Gel in tubes and Injectables. Its operational area covers all over Bangladesh with a large number of field forces who strive hard to establish the demand of products of the company in every corner of the country. The company maintains four outside Depots located at Khulna, Bogra, Chittagong and Sylhet besides its National Distribution Cell in Dhaka. When Ambee Pharmaceutical Ltd.(APL) was launched back in Feb’ 1976, Ambee had only 30 field forces...
Words: 5420 - Pages: 22
...Policy Elements Holly Regan HSM/240 January 31, 2014 Terra Harris Policy Elements This paper will discuss and provide information on six fundamental policy elements which no social policy or program could operate without. The Cocoon House would not have steadily flourished if it had not been made possible the many donors to its organization, which annually provides the main ingredient for The Cocoon House to serve its target population and the community it serves. The mission of The Cocoon House is to foster personal growth and healthy relationships to strengthen and empower at-risk homeless youth and their families. To carry out this mission the agency has developed a continuum of services to serve homeless, at-risk and highly disconnected youth in Snohomish County, Washington by providing housing, prevention and street outreach services, (Cocoon House, 1991). Cocoon House goals and objectives consist of supporting teens in achieving a variety of life skills, educational and professional goals, healthy relationships and a supportive network of friends, family and community. According to The Cocoon House, the Forms of delivered services provided by The Cocoon House are 24 hour access to medical care and supportive services for at-risk youth 13-17, food and emergency shelter/transitional housing services, street outreach and support/advocacy, intensive case management, chemical dependency education, counseling and treatment, mental health counseling, and life...
Words: 345 - Pages: 2
...Bangladesh’s growing pharmaceutical sector The export value of pharmaceuticals is growing at a reasonable rate every year. Exports increased from $8.2 million in 2004 to $28.3 million in 2007 and posted further gains last year. Export destinations are also increasing in number. Beginning in the 1950s, when a few multinationals and local entrepreneurs set up manufacturing facilities in the then East Pakistan, now over 200 companies produce now medicines in Bangladesh. The pharmaceutical industry in Bangladesh has otherwise the potential to grow and enjoy a number of competitive advantages. Quality assurance has put the industry on a solid base. Almost all companies follow the World Health Organisation (WHO) Good Manufacturing Practice (GMP) standards. Bangladesh’s strict quality compliance gives pharmaceuticals an advantage to compete with producers in India, China, Brazil and Turkey in the overseas export markets. The capability of the industry has helped it achieve excellence as per the general international standards. A good number of local pharmaceutical companies have won accreditation from the overseas regulatory authorities including some of those in the developed countries. Two such local companies have been accredited by EMEA (Austria) and the Therapeutic Goods Administration (TGA-Australia). The accreditation facilitates their entry into the lucrative market as reputed players. Bangladesh’s national drug policy requires strict standards compliance from the pharmaceutical...
Words: 686 - Pages: 3
...MAIN INGREDIENT IN PANCAKES PRECIOUS BALGUNA JEROME PIO CHRISTOPHER TAMBOGON JEAIA ARIGUIN APPLE VILLACENTINO RODELYN COLOMA LEO MARK ULEP Researchers DR. EVA MACUGAY Research Adviser ABSTRACT Title: THE UTILIZATION OF TIYESA (Pouteria lucuma) AS MAIN INGREDIENT IN PANCAKES Researchers: PRECIOUS BALGUNA, JEROME PIO,CHRISTOPHER TAMBOGON, JEAIA ARIGUIN, APPLE VILLACENTINO, RODELYN COLOMA, LEO MARK ULEP Research Adviser: Dr. Eva Macugay University: Mariano Marcos State University - College Of Teacher Education Brgy. 5, Castro Avenue, Laoag City This study was designed to determine the feasibility of tiyesa (Pouteria lucuma) fruit as pancake ingredient. The data on the organoleptic tests like appearance, texture and taste were used. The acceptability test used 5 Points Hedonic scale with corresponding numerical score (Highly acceptable, very acceptable, acceptable, not so acceptable, not acceptable). Thirty (30) respondents were randomly selected at Brgy.10, San Jose and Brgy. 9, Sta. Angela, Laoag City. Results were statistically treated using mean average scores. The formulation made of 25% tiyesa (Pouteria lucuma) + 75% flour was recommended for making pancakes. The product was rated the most preferred in terms of taste, appearance and acceptability. It was recommended that further improvement of appearance, texture and taste should be done to make the product better. The researchers also recommend the search for other ingredients that...
Words: 2975 - Pages: 12
...1. Historical background Beximco Pharmaceuticals Limited (BPL) is a part of Beximco Group, the largest private sector industrial conglomerate in Bangladesh. BPL develops, manufactures and markets both finished dosage form branded generic pharmaceutical products and active pharmaceutical ingredients (APIs), with products including solid dose forms, Metered Dose Inhalers, Nasal Sprays, Large Volume Intravenous Fluids, Suppositories, and Creams/Ointments. BPL produces and markets 'branded generics' for most diseases ranging from AIDS to cancer, from infection to asthma, from hypertension to diabetes, for both national and international markets. The company also manufactures active pharmaceutical ingredients and intravenous fluids and contract manufacture for major international brands of leading multinational companies. BPL utilizes state of the art manufacturing facilities. BPL also has outstanding reverse engineering capabilities. Incorporated in 1976, BPL started off as a distributor of pharmaceutical products. It imported products from global MNCs such as Bayer AG of Germany and Upjohn Inc. of USA and sold them in the local market. It eventually graduated to a manufacturer and distributor of these products in local market under licensing agreements. During the early 80s, BPL launched its own products in the local market. Beximco started its exports operation in the early 90s with APIs. Today BPL is one of the largest exporters of medicines from Bangladesh. BPL employs more...
Words: 1988 - Pages: 8
...1.0 Introduction 1.1 Overview of Pharmaceutical Industry In Bangladesh Pharmaceuticals industry is the heart of the healthcare sector of Bangladesh. After liberation in 1971, the industry was largely dominated by MNCs, and the country was highly import dependent. In 1982, through the formulation of national drug policy, and drug control ordinance, a defined guideline for the development of the industry was created. One of the fastest growing sectors with an annual average growth rate consistently in the double digits, the Bangladesh Pharmaceutical industry contributes almost 1% to the nation’s GDP. According to the UKTI (April, 2010) the total size of the pharmaceutical market of Bangladesh was estimated to be US$700 million in 2007. The retail market is about 90% of the total market. In that respect, the total market size is more than BDT 60 billion.(Chowdhury, 2010) The industry produced medication worth $715 million in 2007 with the market growing over 12% annually over the last half a decade and firms primarily focus primary on branded generic final formulations by using mostly imported APIs. According to the World Bank report (2008) about 80% of the drugs sold in Bangladesh are generics and 20% are patented drugs. The country manufactures about 450 generic drugs for 5,300 registered brands which have 8,300 different forms of dosages and strengths. These include a wide range of products from anti-ulcerants, flouroquinolones, anti-rheumatic non-steroid drugs, non-narcotic...
Words: 2034 - Pages: 9
...demands of the overall org? - to what extent should IT at affiliates be centrally controlled - overall question: how IT could best serve the rest of the company - Define Richter’s IT in the past and present o structure, system, strategy - Value of it to Richter - Evaluate current IT governance - Recommend in planning for the coming year Industry - growth due to growing aging population in NA, Europe & Japan - 10 major players; 1000 smaller companies - focus: pipeline – new drugs in the process of development - 15% of sales into R&D - generics: 20-30% decrease in price after patent expiration - GENERIC DRUG COMPANIES: o majority of revenues from selling generic drugs + generic active pharmaceutical ingredients (APIs) o sell packed version of the drug under own name or o sell generic APIs to other pharmaceuticals – package and sell o strict regulatory approval o success: low-cost production capabilities, distribution networks and ability to navigate through complex industry regulations o highly competitive market History Richter - innovation, many patents - export to countries outside the Eastern Bloc - distribution through Medimpex – ensure quality standards - market open up (1990s) o int. companies: tremendous resources & product quality o marketing expertise was lacking - 1992: o minimal technological + financial resources o split up of Medimpex – take over by Richter presence in US,...
Words: 281 - Pages: 2
...at work Annual Report 2009-10 Contents Management Discussion and Analysis ............................. 01 Directors’ Report ....................... 26 Historical Performance .............. 29 Key Performance Indicators ....... 30 Corporate Information .............. 32 Auditors’ Report ........................ 36 Balance Sheet ............................ 40 Profit and Loss Account ............. 41 Cash Flow Statement ................. 42 Statement Relating to Subsidiary Companies ................ 71 Corporate Governance ............... 72 Auditors’ Report - Consolidated ........................... 83 Consolidated Balance Sheet ....... 84 Consolidated Profit and Loss Account ...................... 85 Consolidated Cash Flow Statement ................. 86 At work The cover depicts an artist’s representation of a gyroscope. Encyclopedia Britannica says the 19th C French physicist Foucault gave the name gyroscope to a wheel or rotor mounted in gimbal rings. Such a spinning wheel maintained its original orientation in space regardless of the Earth’s rotation, which made it ideal as a direction indicator. Gyroscopes are used in compasses and automatic pilots on ships and aircraft, in the steering mechanisms of torpedoes, and in the inertial guidance systems installed in space launch vehicles, ballistic missiles, and orbiting satellites. The steadfastness of the gyroscope is quite like the philosophy we work by at Sun Pharma. Staying the course, steady and consistent, despite...
Words: 41744 - Pages: 167
...CIPLA LTD. Mahesh Bhalala Roll no-3 UNDER GUIDANCE OF DR. ANIL ANGRISH NIPER Company Discription Founded in 1935, Cipla is the second largest pharmaceutical company in India with market share of 5.4% in FY10. Company offers various drugs and healthcare products with major share in many therapeutic categories & in most dosage forms. The company has well diversified product portfolio that includes OTC products, prescription products, flavors and fragrances, pesticides, and animal products. The Company's products are certified by various recognized regulatory authorities namely Food and Drug Administration (FDA), USA; Medicines and Healthcare products Regulatory Agency (MHRA), UK and like. The Company also provides technology services for preparation of product, product and process know how and new developments with various manufacturing facilities and R&D centers located across India. Company's business model is based on international strategic alliances by focusing on pursuing organic growth while reducing capital commitment and regulatory risks. In the US, Cipla has entered into partnership for 118 products with 22 partners. Number of partners has increased from 17 to 22 over the last 12 months. Of the pipeline of ~100 ANDAs filed till date, 57 have been approved (35 commercialized)while 45ANDAs are awaiting approval.In addition, Company has developed a strong presence in the 170 countries including both developed and developing countries and derived 55.4% of its...
Words: 1755 - Pages: 8
...Medicom INDEX |Chapter | |Page No | |Introduction Of Samson H. Chowdhury | | |Recognize |2-3 | | |Personal Life | | |Biography Of Samson H. Chowdhury | | |Early Life |4-24 | | |Life In Navy | | | |Job At Post Office | | | |Involvement Of Church | | | |Demise | | | |Position | | ...
Words: 9611 - Pages: 39
...Introduction This Report is based on portfolio background information based around SQUARE Pharma and current trading environment including export-Import trends of SQUARE, FDI prospects and challenges, global production, globalization and its impact in business, research and development of SQUARE and Ethical issues involved in international business. As SQUARE is the top local pharmaceuticals company of Bangladesh so we have chosen it for our report so that we can have a wider view of our concern topics. Basically what we want to cover is the current export situation of the company, the problem that it is facing and solutions they are applying. Besides these we have also recommended some suggestions from our end which can be applied for the betterment of their export business. Objectives We have divided the objective of this report into two parts. One is general and the other is more specific. These objectives are stated below: ❖Primary objectives: Basically our initial objective was to complete the assigned task of term paper for the course of International Business. The topic with which we were assigned was identifying problems and solution of a particular company of export-import industry of Bangladesh. While completing this task firstly we have chosen SQUARE Pharmaceuticals Ltd. Bangladesh because it is the topmost local pharmaceuticals in our country. ❖Secondary objectives: Main focus of our report was to study the areas as follows: 1. To know about the SQUARE Pharmaceuticals...
Words: 5437 - Pages: 22
...Challenges within a CMO Purification Process A Case Study of Crossflow Micro- and Ultrafiltration 6th European Downstream Technology Forum September 7, 2010, Sartorius College, Goettingen Agenda I. II. Introduction Overview applications for CFF at RHB III. Case study I & II IV. Strategies to maintain quality Richter-Helm offers services for (co-)development and manufacture of biopharmaceuticals Business Units and Services In- & Out-Licensing Marketing & Sales Contract development Contract manufacturing Business Development Team GMP-Production Facility, Bovenau 3 Richter-Helm was one of the first companies to produce recombinant proteins in accordance to GMP-guidelines History of Richter-Helm Timeline 1987 1989 1993 1998 2000 2001 Foundation of Pharma Biotechnologie Hannover and start of GMP production Entering contract GMP manufacturing Broadening service portfolio / establishment of contract development services Building up of development centre in Hamburg Planning and start of construction of the new large scale GMP facility in Bovenau First long-term commercial development and supply agreement for large scale facility signed Initiation of GMP production in Bovenau Acquisition by Gedeon Richter Plc and HELM AG Start of in-house development projects Fully remodelled Hannover facility in operation Capacity enlargement in Bovenau More than 20 years of experience in biopharmaceuticals production 3 development and production locations 2003...
Words: 1064 - Pages: 5
...POSITION |NAME |SIGNATURE |DATE | | |Author |Steve Hocking | | | |Global Operations Director |Paul Balkwell | | | |Global Quality Manager |Susan Lewis | | | |REVISED BY |DATE |ACTION |QA APPROVED BY |DATE | | | | | | | | | | | | | | | | | | | | | | | | | Purpose The purpose of this document is to provide clear guidance in the handling of pharmaceutical shipments that are to be shipped on the PDP National and International...
Words: 8740 - Pages: 35
...CASE 6-3 “Eli Lilly in India: Rethinking the Joint Venture Strategy” 1. I think Eli Lilly pursued the right strategy joining Ranbaxy Laboratories to enter the Indian market. While companies were using the global market to amortize the huge investments required to produce a new drug, they were hesitant to invest in countries where the intellectual property regime was weak. During the 1990s both companies had a strong reason for the joint venture. Ranbaxy wanted to make its presence globally and Lilly wanted to get their feet on Indian grounds. In 1992, Ranbaxy approached Lilly to investigate the possibility of supplying certain active ingredients or sourcing of intermediate products to Lilly in order to provide low cost sources of intermediate pharmaceutical ingredients. Based on the strategic alliance, Ranbaxy would supply certain products to the joint venture from its own portfolio that were currently being manufactured in India and then formulate and finish some of Lily’s products locally. From the beginning, both companies had a lot in common, they both believed in high ethical standards, technology and innovation, and future of patented products. They created the joint venture with $7.1 million capital and an initial subscribed equity capital of $3 million, with equal contribution from Lilly and Ranbaxy, leading to an equity ownership of 50 percent each. India, with an 800 million population had about 300 million of people that were considered to...
Words: 855 - Pages: 4
...talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking this medicine against the benefits they expect it will have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. WHAT LOPEDIUM IS USED FOR This medicine is used to treat diarrhoea. It contains the active ingredient loperamide hydrochloride. It works by making the stool more solid and less frequent. It does this by normalising muscle contractions of the intestine. This allows the bowel time to absorb water and produce a more solid stool. Ask your doctor if you have any questions about why this medicine has been prescribed for you.Your doctor may have prescribed it for another reason. This medicine is not addictive. BEFORE YOU TAKE LOPEDIUM When you must not take it Do not take this medicine if you have an allergy to: * loperamide (as hydrochloride), the active ingredient, or to any of the other ingredients listed at the end of this leaflet under Product Description * any other similar medicines. Some of the symptoms of an allergic reaction may include: * shortness of breath * wheezing or difficulty...
Words: 1880 - Pages: 8
